Efficacy of the superoxide dismutase mimetic tempol in animal hypertension models: a meta-analysis

• Published in: Journal of hypertension Vol. 33; no. 1; pp. 14 - 23
• Main Authors: Dornas, Waleska C, Silva, Maísa, Tavares, Ricardo, de Lima, Wanderson G, dos Santos, Rinaldo C, Pedrosa, Maria L, Silva, Marcelo E
• Format: Journal Article
• Language: English
• Published: England Wolters Kluwer Health | Lippincott Williams & Wilkins 01-01-2015
• Subjects: Animals; Antioxidants - therapeutic use; Biomimetic Materials - pharmacology; Biomimetic Materials - therapeutic use; Blood Pressure - drug effects; Blood Pressure - physiology; Cyclic N-Oxides - pharmacology; Cyclic N-Oxides - therapeutic use; Disease Models, Animal; Hypertension - drug therapy; Hypertension - metabolism; Rats; Spin Labels; Superoxide Dismutase - pharmacology; Superoxide Dismutase - therapeutic use; Superoxides - metabolism
• ISSN: 0263-6352; 1473-5598
• DOI: 10.1097/HJH.0000000000000422

OBJECTIVE:Considering the growing body of evidence that indicates the contribution of superoxide anions (O2) and other reactive oxygen species (ROS) to the development of hypertension, we assessed whether animal models of hypertension have a benefic effect with tempol, a superoxide dismutase mimetic, to help augment the design of future studies.
METHODS:Studies published between July 1998 and December 2012 on blood pressure (BP) in different hypertensive models were obtained after an electronic and manual search of PubMed. In-depth analyses of the methodological quality of the studies and the mean arterial pressure (MAP) changes after treatment with tempol were performed, as well as the subgroup analyses on the route of tempol delivery.
RESULTS:Out of the 144 identified studies, 28 were included after screening. The data showed that tempol reduced MAP by computing the standardized mean difference with the value of 4.622 (95% confidence interval 3.24–5.99). The quality of studies included in the meta-analysis was category II; however, omission of details in the trials might have biased the results. There was substantial heterogeneity in the results with an I of 94.45%, which persisted after stratifying for the route of tempol delivery.
CONCLUSION:In conclusion, this analysis shows that antioxidant treatment with tempol can reduce BP, suggesting that ROS plays a role in the pathogenesis of increased BP in the hypertension models used in the current research practice.